← Leaderboards
David H Spencer
Washington University
$4,158,658
Attributed
$6,079,588
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,079,588 · 7
By mechanism
R37$1,406,237 · 1
U01$1,384,429 · 1
R33$1,143,058 · 1
K08$831,490 · 1
R01$664,174 · 1
UH3$388,750 · 1
Top collaborators
- Eric J Duncavage8 shared
- Marina Y Konopleva4 shared
Most similar at Washington University
Same institution · by research overlap
- Paul H Taghert$19,059,948
- Elaine R Mardis$11,835,945
- Eric J Duncavage$2,152,736
- J Evan Sadler$26,812,449
- Donald Michael Nelson$2,281,842
Others in their field
Top investigators on “Mutation”
- Richard A Gibbs · Baylor College Of Medicine$276,143,183
- David Heimbrook · Leidos Biomedical Research, Inc.$175,834,894
- Randall J Bateman · Washington University$154,391,630
- Eric Martin McDade · Washington University$96,219,353
- Stacey Gabriel · Massachusetts Institute Of Technology$95,141,374
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$93,475,056
Research focus
MutationSamplingMalignant NeoplasmsNovel StrategiesLeukemiaSomatic MutationCellsGenesAcute Myelocytic LeukemiaPatternFutureGenome EditingReagentDesignMutantModificationAffectDna MethylationAcute Myeloid Leukemia CellGenomicsChromatinGene Expression RegulationHematopoieticExperimental Study
Grant awards (21)
Genome sequencing for evaluating the efficacy, specificity, and safety of human genome editing$458,717
U01 · FY2025 · AI · contact PI
Whole Genome Sequencing for Genomic Evaluation and Risk Stratification of Patients with Myelodysplastic Syndromes$388,750
UH3 · FY2025 · CA
A Rapid and Comprehensive Approach for Clinical Genomic Profiling in Lung Cancer$387,195
R33 · FY2025 · CA
Dysregulated genome architecture in acute myeloid leukemia$355,706
R37 · FY2025 · CA · contact PI
Genome sequencing for evaluating the efficacy, specificity, and safety of human genome editing$461,687
U01 · FY2024 · AI · contact PI
A Rapid and Comprehensive Approach for Clinical Genomic Profiling in Lung Cancer$367,837
R33 · FY2024 · CA
Dysregulated genome architecture in acute myeloid leukemia$337,922
R37 · FY2024 · CA · contact PI
Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen$251,829
R01 · FY2024 · CA
Genome sequencing for evaluating the efficacy, specificity, and safety of human genome editing$464,025
U01 · FY2023 · AI · contact PI
A Rapid and Comprehensive Approach for Clinical Genomic Profiling in Lung Cancer$388,026
R33 · FY2023 · CA
Dysregulated genome architecture in acute myeloid leukemia$352,328
R37 · FY2023 · CA · contact PI
Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen$45,505
R01 · FY2023 · CA
Dysregulated genome architecture in acute myeloid leukemia$360,281
R37 · FY2022 · CA · contact PI
Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen$270,880
R01 · FY2022 · CA
Whole Genome Sequencing for Genomic Evaluation and Risk Stratification of Patients with Myelodysplastic Syndromes$261,450
UH2 · FY2022 · CA
Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen$95,960
R01 · FY2022 · CA
REGULATORY MECHANISMS OF HOX GENE EXPRESSION IN ACUTE MYELOID LEUKEMIA$166,298
K08 · FY2019 · CA · contact PI
REGULATORY MECHANISMS OF HOX GENE EXPRESSION IN ACUTE MYELOID LEUKEMIA$166,298
K08 · FY2018 · CA · contact PI
REGULATORY MECHANISMS OF HOX GENE EXPRESSION IN ACUTE MYELOID LEUKEMIA$166,298
K08 · FY2017 · CA · contact PI
REGULATORY MECHANISMS OF HOX GENE EXPRESSION IN ACUTE MYELOID LEUKEMIA$166,298
K08 · FY2016 · CA · contact PI
REGULATORY MECHANISMS OF HOX GENE EXPRESSION IN ACUTE MYELOID LEUKEMIA$166,298
K08 · FY2015 · CA · contact PI